Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nudix hydrolase 17 (NUDT17) is an enzyme belonging to the Nudix hydrolase family, characterized by the presence of a highly conserved Nudix box sequence that provides cation binding and catalytic activity[1][2][3]. NUDT17 acts as a hydrolase, most likely functioning in the hydrolysis of nucleoside diphosphate derivatives, including NADH and NADP, and can act as a decapping enzyme for certain monomethylated capped RNAs in vitro[3]. It plays a role in NADH metabolic and catabolic processes, and is predicted to be localized to the peroxisome[3]. NUDT17 is implicated in the regulation of nucleotide pool sanitization and cellular redox state, but its specific biological and disease functions in humans remain largely uncharacterized and require further study[1][3]. Diseases associated with NUDT17 include alpha thalassemia-intellectual disability syndrome type 1, and it shares similarity with other family members like NUDT12[3].
Catalytic hydrolysis of capped RNA and nucleoside diphosphate derivatives
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nudix hydrolase 17 (NUDT17).